Navigation Links
Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients

Hematide in hemodialysis patients with stable baseline Hgb levels between 10 and 12.5 g/dL on previous Epoetin Alfa therapy. The endpoints were Hgb and reticulocyte levels, Hematide dose adjustments and red blood cell transfusions. In addition, adverse and serious adverse events were monitored.

Pharmacodynamic data were presented on the 90 patients who had completed six months of treatment. Mean reticulocyte increases were observed after every Hematide injection. The mean Hgb level, which was 11.5 g/dL at baseline, was maintained within +/- 1 g/dL at the end of six months of treatment. In the 165 patients who received drug in this study, Hematide was generally well tolerated with an adverse event profile consistent with the hemodialysis patient population.

About Hematide

Hematide is a novel synthetic, pegylated peptide that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in chronic kidney disease and cancer.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel peptide-based drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic kidney disease and cancer. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding the timing, design and results of the Company's clinical trials and drug development program, the timing and likelihood of the commercialization of Hematide. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, the potential for once per month dosing, regulatory requirements and approvals, research and deve
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
2. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:3/5/2015)... , March 5, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, announced ... Annual ROTH Conference, to be held March 8-11, ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:3/5/2015)... , March 5, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, announced today that ... top rehabilitation hospitals for spinal cord injury and brain ... trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured ... injury (SCI). The Phase 1/2a trial ...
(Date:3/5/2015)... and VANCOUVER, British Columbia ... BUX FSE: 20B OTCQB: BMKDF) -- The ultimate goal ... assay that is capable of detecting tumors before they ... years, the development of such an assay has been ... academia and industry. Although many breakthrough diagnostics have been ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4
... Kendle (Nasdaq: KNDL ), a leading, global full-service clinical research organization, today ... on June 23, 2010 , at the InterContinental Hotel in Boston . ... Kendle,s formal presentation will be given by Chairman ... Time . , , , ...
... June 17 Brainlab AG today announced that it ... business unit of the Toshiba Group, to integrate its Aquilion™ LB ... operating room (OR). , , ... Stephan Holl , Chief Operating Officer, Brainlab, indicated that ...
Cached Medicine Technology:Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 3
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 Shania Twain ... in more than a decade. She has hinted that this ... to miss seeing her perform one last time. She has ... and this beloved country sweetheart has millions of loyal fans around ... throughout her native country, Canada, and on June 30th she will ...
(Date:3/5/2015)... 2015 This week, 60 ... low-cost laminate flooring products, initiating widespread concern from ... building materials made primarily from bamboo, stands behind ... their flooring products for volatile organic compounds (VOCs) ... International (BMH). Results from formaldehyde emissions testing ...
(Date:3/5/2015)... A Bakersfield, Calif. state court jury returned ... awarding the plaintiff Coleen M. Perry a total of $5.7 ... TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, Inc., a ... a partner at Wagstaff & Cartmell in Kansas ... along with Rich Freese and Tim Goss of Freese ...
(Date:3/5/2015)... 05, 2015 AxoGen, Inc. (NASDAQ: ... the peripheral nerve repair market, reported record revenue of ... 2014 compared to $2.98 million in the year-ago fourth ... strategies. , “Our strong fourth quarter revenue growth ... repair products which is driving increased surgeon adoption of ...
(Date:3/5/2015)... March 05, 2015 Risperdal lawsuits ... a Pennsylvania mass tort litigation currently underway in ... jury has begun hearing testimony in the proceeding’s ... antipsychotic medication can cause gynecomastia, or male breast ... question was filed on behalf of a plaintiff ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... CEO, Will Continue Serving as Chairman of the Board, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... Martin, Chief Executive Officer of the Company,s,medical division, as ... of its Board,of Directors, effective January 1, 2008. As ...
... Detection and treatment of tumours, diseased blood vessels and ... an innovative imaging system being developed that uses both ... extremely short pulses of low-energy laser light to stimulate ... area being examined. These waves are then converted into ...
... Amsterdam, December 12, 2007 Elsevier, a leading ... today announced that 45 French-language medical journals from ... January 3, 2008. , The titles, including Feuillets ... Mdicale, represent a wide range of high-quality journals ...
... by 81 percent of Michigan adults, DETROIT, Dec. ... of reform measures proposed in the Michigan Legislature,that would ... increases and set standard rating practices for all insurers ... made public today,by Blue Cross Blue Shield of Michigan., ...
... TITUSVILLE, N.J., Dec. 12 INVEGA(TM) (paliperidone),Extended-Release ... a one-year open-label extension (OLE) study, according ... symptom scores improved or,were stable, on average, ... was designed to evaluate the long-term safety ...
... it. Hair Fairies - The Head Lice, Helpers - is here to ... ... No two words in the English language,can stop every parent in ... other kid-centric services are often,sent into crisis mode when an outbreak occurs, ...
Cached Medicine News:Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 2Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 3Health News:Light and sound -- the way forward for better medical imaging 2Health News:ScienceDirect to host French-language journals from Elsevier Masson 2Health News:Overwhelming Majority of Michigan Residents Favors Individual Health Insurance Market Reforms Supported by Blue Cross Blue Shield of Michigan 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 4Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 5Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 6Health News:Head Lice Removal Service Opens in Chicago 2Health News:Head Lice Removal Service Opens in Chicago 3
... fixed-volume, adjustable-volume, and multichannel models as ... pro Pipette. Designed with a separate ... have earned a worldwide reputation for ... original Eppendorf pipette tips, they provide ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Research Family includes fixed-volume, adjustable-volume, and ... electronic Eppendorf Research pro Pipette. Designed ... compact, high-performance pipettes have earned a ... for use with original Eppendorf pipette ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: